VSTM

Verastem Inc. (VSTM) | Rumor.io

Verastem

VSTM

Attention (50-day avg)0.01%

Attention rank (50-day avg)#422

Bullish sentiment (50-day avg)78%

Price to earnings ratio-2.58

Market capitalization703.7M

Earnings per share-2.44

Dividend yield (TTM)—

Revenue (annual)30.9M

Net income (annual)-209.5M

Social

What share of all stock conversation is about VSTM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.02% +0.02	0% 0

Sep 22

Verastem, Inc. (VSTM) is experiencing increased attention, with its conference call impressing investors and collaborations discussed.
The company's recent study showed good results, but a Chinese equivalent of the trial revealed high toxicity, which could impact VSTM's stock price if the toxicity is present.
Verastem's stock is consolidating nicely at its current levels, building a base for a potential move up, and investors are optimistic about its future prospects.

Generated by AI

Sentiment

Of the messages about VSTM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +29.41	81.54% -3.38	76.55% -7.68
Bearish	—	0% -29.41	18.46% +3.38	23.45% +7.68

Bullish· Sep 2

Verastem, Inc. (VSTM) has broken above a descending channel on strong volume, indicating a potential upward trend.
The stock has cleared key resistance and seen a bullish crossover in the MACD, with expanding volume providing support.
VSTM's price action has been strong, with a rising tide in the sector, significant volume, and multiple analysts predicting a sustained upward momentum.

Bearish· Jun 25

The company's stock price has declined significantly, with some expecting it to drop below $3.
The decline in stock price is attributed to concerns over an upcoming equity offering, which may have already been priced into the market.
The management team is criticized for its handling of the company, with some describing it as one of the worst in the biotech space.

Generated by AI

Topics

Of the messages about VSTM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80.28%	62.11%
Technical Analysis	—	0%	4.23%	19.2%
Earnings	—	0%	15.49%	8.87%
Analysts	—	0%	0%	7.02%
Controversies	—	0%	0%	0.66%
Macro	—	0%	0%	2.13%

Earnings· May 7

Verastem, Inc. ($VSTM) reported a loss of $0.35, beating the consensus estimate of ($0.19).
The company beat revenue estimates by $1.27M, reporting $5M in revenue for Q1.
Verastem's EPS miss was partially offset by a significant revenue beat, with the company reporting a 190% year-over-year increase in revenue.

Analysts· Sep 25

$VSTM's price target was raised to $15 by H.C. Wainwright, with other analysts also increasing their targets to $14, $16, and $17.
Analysts at H.C. Wainwright, BTIG, and Oppenheimer maintained BUY ratings with targets of $15, $17, and $16, respectively.
The upcoming December ASH conference is expected to be a catalyst for the stock, with analysts citing the potential for new data and a significant increase in the price target.

Announcements· May 26

Verastem Inc. has appointed Karin Tollefson as its new CEO, bringing 30 years of experience in the pharmaceutical industry, including leadership roles at Eli Lilly and Company.
Verastem Oncology has announced updated data from its RAMP 201 trial, showing an objective response rate of 45% in patients with recurrent low-grade serous ovarian cancer treated with avutometinib and defactinib.
Verastem Inc. shares have surged 131% after the company announced the positive trial results, with the stock being halted for trading due to volatility.

Technical Analysis· May 24

VSTM's price dropped 60% premarket after a 55% increase the previous day, following the release of data after hours.
Traders are watching the stock's bounce potential, with some setting a target price of $5 and others setting stops at $3.15.
The stock's RSI is at 13, with some traders waiting for it to reach the 5-10 range before making a trade.

Generated by AI

Community

Of the messages about VSTM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	6.19%	54.97%
Newcomers	0%	0%	93.81%	45.03%

Regulars· Sep 8

The upcoming investor event on October 14, 2026, will unveil new clinical data highlighting the best-in-class potential of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor across pancreatic, lung, and colorectal cancers.
Verastem Oncology is expected to report on safety and efficacy of VS-7375 in broader tumor types, building on the clinical update reported in June 2026.
The company's confidence in VS-7375's potential is reflected in the early release of the PR and the investor event's timing in the morning, which may indicate a strong data set and a potential positive impact on the stock price.

Newcomers· Sep 2

Verastem's VS-7375 has been given a fast-tracked phase 2 trial by the FDA for pancreatic, lung, and colorectal cancer, with clinical data expected in October.
Newcomers are optimistic about Verastem's future, citing the company's announcements and upcoming healthcare conferences as potential catalysts.
The stock has broken above resistance and seen a surge in momentum, with indicators such as the golden cross and rising volume suggesting a bullish trend.

Generated by AI

News

Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data

2d agoInvesting.com

Verastem to present cancer treatment study data at IGCS meeting

5d agoInvesting.com

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

BOSTON, September 24, 2026--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026

5d agoYahoo Finance

Verastem CFO Daniel Calkins sells $423 in company stock

6d agoInvesting.com

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

8d agoYahoo Finance

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

Detailed price information for Verastem Inc (VSTM-Q) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Also Discussed

Investors talking about VSTM also mention

#	Name	Attention
1	Geron CorporationGERN	0%0
2	MRNS - Marinus Pharmaceuticals, Inc.	——
3	TRVN - Trevena, Inc.	——
4	PRTK - Paratek Pharmaceuticals, Inc.	——
5	Vericel CorporationVCEL	0%0
6	TG Therapeutics Inc.TGTX	0.01%+0
7	MRTX - Mirati Therapeutics, Inc.	——
8	BioLine RX LtdBLRX	0%0
9	EyePoint, Inc. Common StockEYPT	0%0
10	VBIV - VBI Vaccines Inc.	——

Verastem Inc.

Healthcare
Biotechnology

Verastem Inc. is a biopharmaceutical company that concentrates on developing and commercializing innovative cancer therapies. Its primary focus is on creating treatments targeting cancer cell survival and division pathways, specifically in hematologic malignancies and solid tumors. Key products in its pipeline include small molecule inhibitors that aim to disrupt cancer cell signaling and replication processes. Verastem Inc. plays a pivotal role within the healthcare and biotechnology sectors, contributing to advancements in precision medicine through its targeted therapies. Headquartered in Needham, Massachusetts, Verastem's research and development efforts are geared towards addressing unmet needs in oncology by providing new options for patients, thereby enhancing its importance in the biopharmaceutical market landscape. As it continues to make strides in cancer treatment, Verastem Inc. remains an integral player in the ongoing quest for more effective cancer solutions.

Website

Location

117 Kendrick Street

Needham, MA, 02494

United States

Social

What share of all stock conversation is about VSTM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.02% +0.02	0% 0

Sep 22

Verastem, Inc. (VSTM) is experiencing increased attention, with its conference call impressing investors and collaborations discussed.
The company's recent study showed good results, but a Chinese equivalent of the trial revealed high toxicity, which could impact VSTM's stock price if the toxicity is present.
Verastem's stock is consolidating nicely at its current levels, building a base for a potential move up, and investors are optimistic about its future prospects.

Generated by AI

Sentiment

Of the messages about VSTM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +29.41	81.54% -3.38	76.55% -7.68
Bearish	—	0% -29.41	18.46% +3.38	23.45% +7.68

Bullish· Sep 2

Verastem, Inc. (VSTM) has broken above a descending channel on strong volume, indicating a potential upward trend.
The stock has cleared key resistance and seen a bullish crossover in the MACD, with expanding volume providing support.
VSTM's price action has been strong, with a rising tide in the sector, significant volume, and multiple analysts predicting a sustained upward momentum.

Bearish· Jun 25

The company's stock price has declined significantly, with some expecting it to drop below $3.
The decline in stock price is attributed to concerns over an upcoming equity offering, which may have already been priced into the market.
The management team is criticized for its handling of the company, with some describing it as one of the worst in the biotech space.

Generated by AI

Topics

Of the messages about VSTM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80.28%	62.11%
Technical Analysis	—	0%	4.23%	19.2%
Earnings	—	0%	15.49%	8.87%
Analysts	—	0%	0%	7.02%
Controversies	—	0%	0%	0.66%
Macro	—	0%	0%	2.13%

Earnings· May 7

Verastem, Inc. ($VSTM) reported a loss of $0.35, beating the consensus estimate of ($0.19).
The company beat revenue estimates by $1.27M, reporting $5M in revenue for Q1.
Verastem's EPS miss was partially offset by a significant revenue beat, with the company reporting a 190% year-over-year increase in revenue.

Analysts· Sep 25

$VSTM's price target was raised to $15 by H.C. Wainwright, with other analysts also increasing their targets to $14, $16, and $17.
Analysts at H.C. Wainwright, BTIG, and Oppenheimer maintained BUY ratings with targets of $15, $17, and $16, respectively.
The upcoming December ASH conference is expected to be a catalyst for the stock, with analysts citing the potential for new data and a significant increase in the price target.

Announcements· May 26

Verastem Inc. has appointed Karin Tollefson as its new CEO, bringing 30 years of experience in the pharmaceutical industry, including leadership roles at Eli Lilly and Company.
Verastem Oncology has announced updated data from its RAMP 201 trial, showing an objective response rate of 45% in patients with recurrent low-grade serous ovarian cancer treated with avutometinib and defactinib.
Verastem Inc. shares have surged 131% after the company announced the positive trial results, with the stock being halted for trading due to volatility.

Technical Analysis· May 24

VSTM's price dropped 60% premarket after a 55% increase the previous day, following the release of data after hours.
Traders are watching the stock's bounce potential, with some setting a target price of $5 and others setting stops at $3.15.
The stock's RSI is at 13, with some traders waiting for it to reach the 5-10 range before making a trade.

Generated by AI

Community

Of the messages about VSTM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	6.19%	54.97%
Newcomers	0%	0%	93.81%	45.03%

Regulars· Sep 8

The upcoming investor event on October 14, 2026, will unveil new clinical data highlighting the best-in-class potential of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor across pancreatic, lung, and colorectal cancers.
Verastem Oncology is expected to report on safety and efficacy of VS-7375 in broader tumor types, building on the clinical update reported in June 2026.
The company's confidence in VS-7375's potential is reflected in the early release of the PR and the investor event's timing in the morning, which may indicate a strong data set and a potential positive impact on the stock price.

Newcomers· Sep 2

Verastem's VS-7375 has been given a fast-tracked phase 2 trial by the FDA for pancreatic, lung, and colorectal cancer, with clinical data expected in October.
Newcomers are optimistic about Verastem's future, citing the company's announcements and upcoming healthcare conferences as potential catalysts.
The stock has broken above resistance and seen a surge in momentum, with indicators such as the golden cross and rising volume suggesting a bullish trend.

Generated by AI

Verastem

Social

Sep 22

Bullish· Sep 2

Bearish· Jun 25

Earnings· May 7

Analysts· Sep 25

Announcements· May 26

Technical Analysis· May 24

Regulars· Sep 8

Newcomers· Sep 2

Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data

Verastem to present cancer treatment study data at IGCS meeting

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

Verastem CFO Daniel Calkins sells $423 in company stock

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

Also Discussed

Verastem Inc.

Company Information

Location

Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data

Verastem to present cancer treatment study data at IGCS meeting

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

Verastem CFO Daniel Calkins sells $423 in company stock

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

Also Discussed

Social

Sep 22

Bullish· Sep 2

Bearish· Jun 25

Earnings· May 7

Analysts· Sep 25

Announcements· May 26

Technical Analysis· May 24

Regulars· Sep 8

Newcomers· Sep 2